Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.

Christine FujaVishesh KotharyTimothy Clifford CarllSavita SinghPaul MansfieldGeoffrey D Wool

Published in: Transfusion (2022)

We present a case of HHS proximate to recent SARS-CoV-2 infection with multiple allo and autoantibodies identified. Information on the relationship between SARS-CoV-2 infection and HHS is limited; however, it is possible that inflammation related to COVID-19 could predispose to HHS. Tocilizumab is an approved treatment for COVID-19. Additionally, tocilizumab appears to be a promising treatment option for patients with HHS.

Keyphrases

rheumatoid arthritis
coronavirus disease
respiratory syndrome coronavirus
sars cov
juvenile idiopathic arthritis
rheumatoid arthritis patients
oxidative stress
systemic lupus erythematosus
health information
drug administration